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Background: microRNAs (miRNAs) play both oncogenic and oncostatic roles in leukemia. However, the molecular
details underlying miRNA-mediated regulation of their target genes in pediatric B- and T-cell acute lymphoblastic
leukemias (ALLs) remain unclear. The present study investigated the relationship between miR-2909 and Kruppel-like
factor 4 (KLF4), and its functional relevance to cell cycle progression and immortalization in patients with pediatric ALL.
Methods: Elevated levels of miR-2909 targeted the tumor suppressor gene KLF4 in pediatric B-cell, but not pediatric
T-cell ALL, as detected by pMIR-GFP reporter assay. Expression levels of genes including apoptosis-antagonizing
transcription factor (AATF), MYC, B-cell lymphoma (BCL3), P21CIP, CCND1 and SP1 in B- and T-cells from patients with
pediatric ALL were compared with control levels using real-time quantitative reverse transcription polymerase
chain reaction, western blotting, and reporter assays.
Results: We identified two novel mutations in KLF4 in pediatric T-ALL. A mutation in the 3′ untranslated region of
the KLF4 gene resulted in loss of miR-2909-mediated regulation, while mutation in its first or third zinc-finger motif
(Zf1/Zf3) rendered KLF4 transcriptionally inactive. This mutation was a frameshift mutation resulting in alteration of
the Zf3 motif sequence in the mutant KLF4 protein in all pediatric T-ALL samples. Homology models, docking
studies and promoter activity of its target gene P21CIP confirmed the lack of function of the mutant KLF4 protein
in pediatric T-ALL. Moreover, the inability of miR-2909 to regulate KLF4 and its downstream genes controlling cell
cycle and apoptosis in T-cell but not in B-ALL was verified by antagomiR-2909 transfection. Comprehensive
sequence analysis of KLF4 identified the predominance of isoform 1 (~55 kDa) in most patients with pediatric
B-ALL, while those with pediatric T-ALL expressed isoform 2 (~51 kDa).
Conclusions: This study identified a novel miR-2909-KLF4 molecular axis able to differentiate between the
pathogeneses of pediatric B- and T-cell ALLs, and which may represent a new diagnostic/prognostic marker.
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Acute lymphoblastic leukemia (ALL) is widely recognized
as the most prevalent pediatric leukemia [1]; however, the
genomic mechanisms responsible for the uncontrolled cell
proliferation coupled with cell immortalization remain
unknown [2]. In this context, the genes for apoptosis-
antagonizing transcription factor (AATF) and Kruppel like
factor 4 (KLF4) have assumed importance. AATF provides
a critical link between cell cycle progression, check-point
control, and apoptosis [3], and also encodes the novel
microRNA (miRNA) miR-2909, which regulates genes in-
volved in inflammation, cell cycle, and immune response
[4-6]. KLF4, a member of the SP1/KLF transcription factor
family, is characterized by three highly conserved C2H2-
type zinc-finger motifs at its carboxyl terminus, which are
crucial for its interaction with its target DNA [7]. The KLF4
gene acts as both an oncogene and a tumor suppressor,
depending on its genetic and cellular contexts [8]. The
tumor-suppressive role of KLF4 and its involvement in
regulating apoptosis, proliferation, and differentiation in B-
cell malignancies suggest that KLF4 may play a critical role
in leukemogenesis [9]. Furthermore, KLF4 mRNA has been
shown to be targeted by miR-130a and 135b in M1 acute
myeloid leukemic blasts, and silencing of KLF4 arrested the
maturation of blood cells at an early progenitor stage [10].
The discovery of miRNAs has opened a new epige-
nomic dimension in terms of the understanding of onco-
genesis in general and leukemogenesis in particular [11].
Alterations in miRNA expression patterns and their
respective targets have been documented in various
tumors [12] including different types of leukemias such
as chronic lymphocytic leukemia [13], acute myeloid
leukemia [14] and ALL [15], thus suggesting a possible
correlation between miRNA expression status and the
development of hematological malignancies.
The present study aimed to identify the expression sta-
tus of AATF-encoded miR-2909 in B- and T-cells from
patients with pediatric ALL and explore the possible
relationship between miR-2909 and KLF4 in these cells.
We also investigated the functional importance of this
relationship in the regulation of genes involved in cell
cycle progression (BCL3, CCND1, MYC) and apoptosis
(AATF). To the best of our knowledge, the results of this
study provide the first evidence for miR-2909-dependent
regulatory pathway as the possible underlying mechan-
ism responsible for the initiation of ALL in humans.
Results
miR-2909 targets KLF4
Quantitative real-time polymerase chain reaction (PCR)
analysis of miR-2909 expression in 30 pediatric patients
with B-ALL and 20 with T-ALL revealed significantly in-
creased expression levels compared with the corresponding
controls (Figure 1A). To investigate the molecularmechanism of miR-2909 function in ALL, we performed
in silico screening of genes reported to play crucial roles in
leukemogenesis for the presence of miR-2909 target site(s)
using an RNA hybrid tool (http://bibiserv.techfak.uni-
bielefeld.de/rnahybrid/) [16]. Among all the identified
genes, we focused on KLF4 because it was reported to be
significantly downregulated in ALL and functions as a
tumor suppressor in B-cell hematological malignancies
[9]. The 3′ untranslated region (UTR) region of KLF4 har-
bored a target site for miR-2909 (Figure 1B). To validate
this prediction experimentally, KLF4 expression was ob-
served at both the mRNA and protein levels in patients
with ALL. Increased miR-2909 expression was always ac-
companied by significant downregulation of KLF4 mRNA
and protein in pediatric B-ALL compared with controls,
indicating that miR-2909 may regulate the expression of
KLF4 by targeting its 3′UTR (Figure 1C and D). In con-
trast, both mRNA and protein expression levels of KLF4
were upregulated in T-ALL compared with controls
(Figure 1C and D), despite increased expression of miR-
2909 in these T-ALL lymphoblasts (Figure 1A), suggesting
the possibility of a mutation in either the seed sequence or
the 3′UTR region of KLF4 involving the miR-2909 bind-
ing site.
Melting-curve graphs for miR-2909 found no differ-
ence between T-ALL and controls, thus ruling out the
presence of a mutation in the seed sequence of miR-
2909 (Figure 1E). However, the melting-curve graph cor-
responding to the KLF4 3′UTR did show a significant
difference (Figure 1F). In order to clarify these changes,
amplicons corresponding to this region were sequenced
and revealed the presence of a genetic aberration in the
miR-2909-binding site of KLF4 in T-ALL (Figure 2A).
In contrast, no aberration was depicted in the miR-
2909-binding site within the 3′UTR of KLF4 in B-ALL
(Figure 2B). To further confirm if miR-2909 targets KLF4
in pediatric B-ALL but not in pediatric T-ALL, we
constructed reporter plasmids using the KLF4 3′UTR
containing the miR-2909 target site from B-ALL (pGFP-
KLF4-3′UTR-B) and T-ALL (pGFP-KLF4-3′UTR-T) pa-
tients (Figure 2D). The 3′UTR regions of the KLF4
genes from both B-ALL and T-ALL were amplified and
inserted into the cloning site of the vector downstream
of the green fluorescent protein (GFP) reporter gene.
These plasmids were then transfected into HEK 293
cells, which intrinsically overexpressed miR-2909 com-
pared with HeLa, PC3 and HepG2 cells (Figure 2C).
HEK 293 cells carrying pGFP-KLF4-3′UTR-B exhibited
a 52.07% reduction in GFP expression, whereas cells
expressing pGFP-KLF4-3′UTR-T showed no noticeable
difference compared with cells transfected with pGFP
plasmid without 3′UTR inserts (Figure 2E and F). These
results clearly revealed the ability of miR-2909 to repress
KLF4 expression in pediatric B-ALL, but not T-ALL.
Figure 1 miR-2909 and KLF4 expression in pediatric acute lymphoblastic leukemias. (A) qRT-PCR analysis for relative expression of miR-
2909 in patients with pediatric B-ALL and T-ALL compared with the corresponding controls. Expression was normalized to U6 snRNA; error bars
represent mean ± S.D. n = 6, **P < 0.01 relative to B-and T-control. (B) Bioinformatics analysis of miR-2909 target site in the 3′UTR of KLF4 gene
(C-D) KLF4 expression level at the mRNA (C) and protein (D) in patients with pediatric ALL compared with the corresponding controls. β-actin
was used as an invariant control; each bar represents mean ± S.D of the experiment performed in triplicate *P < 0.05 relative to B-and T-control;
densitometric analysis of western blot results was performed using Scion Image Analysis Software. (E-F) Melting curve graphs of hsa-miR-2909
(E) and KLF4 3′UTR (F) respectively in pediatric T-ALL. Difference between melting curve graph for KLF4 3′UTR in T-ALL and control is indicated by
asterisk (*).
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UniProt gives three different isoforms of KLF4. Isoform 1
has the addition of 33 amino acids at location 367–400
while isoform 3 has a deletion of the first 50 amino acids
(http://www.uniprot.org/uniprot/O43474) [17]. We aimed
to determine if the isoforms of KLF4 differed between
B-ALL and T-ALL. The amplicons corresponding to full-
length KLF4 were sequenced in 30 B-ALL and 20 T-ALL
samples. Strikingly, 25 B-ALL samples showed the pres-
ence of isoform 1, which incorporated an intronic region
between exons 3 and 4 in the coding sequence resulting in
an increased molecular mass of approximately 55 kDa
(total length of 513 amino acids). The remaining five B-
ALL and all 20 T-ALL samples showed the presence of
isoform 2, containing 479 amino acids with a molecular
mass of 51 kDa (Figure 3A and B).We further explored if T-ALL patients expressed iso-
form 3 of KLF-4. Sequencing failed to identify any dele-
tion of the first 50 amino acids in any of the T-ALL
samples in the present study, confirming the absence of
isoform 3 in these blast cells (Figure 3C). Interestingly,
most T-ALL samples showed insertion/deletion of nu-
cleotides in the region corresponding to the third zinc-
finger (Zf3) motif of KLF4, while deletion of nucleotides
in the first zinc-finger (Zf1) motif was identified in some
T-ALL samples (Figure 3D, Additional file 1: Figure S1).
These genetic aberrations changed the entire reading
frame, altering the sequence of the KLF4 zinc-finger
motif and potentially destroying its DNA-binding affinity
(Additional file 1: Figure S1G). Modeling/docking stud-
ies were performed using mutant KLF4 lacking the Zf3
motif but with intact Zf1 and Zf2 motifs derived from
Figure 2 miR-2909 targets 3′UTR of KLF4 in B-ALL but not T-ALL. (A-B) The sequence alignment of the miR-2909 binding site, located at
491-508 nucleotides within KLF4 3′UTR region in pediatric T-ALL (A) and B-ALL (B). The NCBI sequence is shown for comparison. (C) Endogenous
expression of hsa-miR-2909 in indicated cancer cell lines representing high expression in HEK 293 cells and low expression in HeLa cells using
qRT-PCR. (D) Schematics representing miRNASelect™ pMIR-GFP reporter vector construct containing KLF4 3′UTR and the miR-2909 target site from
both B-ALL (pGFP-KLF4-3′UTR-B) and T-ALL (pGFP-KLF4-3′UTR-T) patients into the cloning site of the vector downstream of the green fluorescent
protein (GFP) reporter gene under the control of CMV promoter. (E) Representative fluorescent microscopic images and FACS results of HEK 293
cells transfected with either control pGFP vector without 3′UTR insert or pGFP-KLF4-3′UTR-B reporter vector or pGFP-KLF4-3′UTR-T reporter vector
following 48 h of transfection. (F) Percentage of cells expressing GFP in transfected cells with indicated constructs was calculated using flow cytometry.
Each bar represents mean percentage ± S.D of cells expressing GFP of the experiment performed in triplicate; * P < 0.05 relative to control.
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also sequenced the KLF4 coding region corresponding
to the three zinc-finger motifs in B-ALL samples to
detect the presence of any genetic aberration(s) in this
region in pediatric B-ALL. Sequence analysis revealed
no genetic aberrations in any of the three zinc-fingers
regions of KLF4 in samples from pediatric patients with
B-ALL, suggesting that the conformation of KLF4 was
unaffected in these patients (Additional file 2: Figure S2).
Molecular modeling and docking studies of KLF4 protein
Sequence alignment of wild-type KLF4 (derived from
control T cells) with mutant KLF4 (derived from pediatricT-ALL samples) revealed that the Zf3 motif was mutated
(Figure 4A). Comparison of structural models of the third
zinc-finger motif between wild-type and mutant KLF4
revealed the amino acid replacements C462V, C465M, and
H482F, which were involved in coordination with zinc
(Figure 4B, C and D). The structure of wild-type KLF4
revealed the existence of a salt bridge between the gua-
nidinium group of arginine residues (R449 and R471)
and the surrounding anionic carboxylate (RCOO-) side
chains of glutamic and aspartic acid (E446 and D473),
respectively. The third glutamate residue (E446) formed
a salt bridge with cationic ammonium (RNH3
+) of lysine
(E446-L453). In contrast, in mutant KLF4, the guanidinium
Figure 3 Sequence analysis of KLF4 coding region in B-ALL and T-ALL samples. (A) Snapshot of KLF4 gene sequence depicting the
predominance of a splice variant (isoform 1) of KLF4 with the addition of 102 nucleotides between exons 3 and 4 in B-ALL samples. This entire
region is absent in T-ALL samples. (B) Protein sequence depicting addition of 367-400 amino acids, confirming the presence of isoform 1 in B-
ALL, while this entire region remains absent in all T-ALL samples in the present study (C) Presence of 1-50 amino acids confirms the existence of
isoform 2 in all T-ALL study samples. The control sequence is shown for comparison. (D) Representative sequence data of pediatric T-ALL-1 sample is
shown. A single nucleotide, T is inserted in the region corresponding to the third zinc-finger (Zf3) motif of KLF4 in T-ALL samples. (E) Genetic
aberration(s) changed the entire reading frame, altering the sequence of KLF4 third zinc finger motif. The NCBI protein sequence is shown for
comparison. Representative DNA and protein sequence alignment of KLF coding region (corresponding to three zinc finger motifs in exon 5) in
other T-ALL samples are shown in Additional file 1: Figure S1.
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+) group of arginine only formed a salt bridge
with the anionic carboxylate (RCOO-) of either glutamic
acid or aspartic acid (E446 and R479, E446 and R479,
D445–R443). The molecular interactions of modeled
wild-type and mutant KLF4 with a 10-bp DNA se-
quence (5′-cgggcggggc-3′) in the P21CIP gene promoter,
which is widely recognized as the transcriptional target
site for KLF4 protein [18,19], revealed that T-ALL mu-
tant KLF4 was unable to interact with its target DNA
sequence as a result of mutation of the Zf3 motif, while
wild-type KLF4 exhibited proper cation-π and hydrogen-
bonding interactions with its target DNA sequence
(Figure 4E). Docking analysis of wild-type KLF4 revealed
that residues Arg458, Lys453, Arg471, and Arg467 dis-
played cation-π interactions with guanine (at positions 11,
6, 7) and cytidine 10 (Figure 4F and G), and residuesHis424 and Ser470 formed hydrogen bonds with guanine
(at positions 20 and 11), respectively (Figure 4G and H).
In contrast, docking of mutant KLF4 with its target
DNA sequence exhibited the formation of hydrogen
bonds between Arg458 and guanine (at position 3) and
cation-π interactions between Arg443 and cytidine14
(Figure 4G). The precise details of other non-covalent
interactions are discussed in Additional file 3: Figure S3.
Loss of transcriptional activity of mutant KLF4 protein
To confirm the bioinformatics result suggesting that
mutant KLF4 was unable to interact with its 10-bp target
sequence in the P21CIP gene promoter in pediatric T-
ALL, we transfected a β-galactosidase (β-gal) construct
under the control of the P21CIP promoter and harbor-
ing a KLF4 site into control and T-lymphoblasts and
Figure 4 Molecular Modeling and docking studies of wild-type and mutant KLF4. (A) Representative sequence alignment of wild-type KLF4
(derived from control T-cells) with mutant KLF4 (derived from pediatric T-ALL samples). The zinc finger motifs Zf1, Zf2 and Zf3 are highlighted
and (*) indicates conserved residues. The grey region indicates third zinc finger motif (Zf3) with mutated amino acids. (B-C) The structure of zinc
finger motifs for wild type (B) and mutant KLF4 (C) were built using MODELLER Program under Accelrys Discovery Studio version 2.5. Zf1; blue,
Zf2; green and Zf3; red. Comparison of structural models of the third zinc-finger motif between wild-type and mutant KLF4 revealed the amino
acid replacements C462V, C465M, and H482F, which were involved in coordination with zinc (D) Superimposition of Zf3 motif of wild-type (pink)
and mutant KLF4 (blue). (E) Molecular interaction of modeled wild-type and mutant KLF4 with its target DNA binding sequence with inserted
table depicting the binding energies of the interacting complexes. (F-G) Docking analysis of wild-type KLF4 revealed that residues R458, K453,
R471and R467 displayed cation-π interactions with guanine (at positions 11, 6, 7) and cytidine 10. In contrast, docking of mutant KLF4 with its
target DNA sequence exhibited cation-π interactions only between R443 and cytidine 14. (H) Docking analysis of wild-type KLF4 revealed that
residues H424 and S470 formed hydrogen bonds with guanine (at positions 20 and 11), respectively. Such interactions were missing in mutant
KLF4 as a consequence of altered sequence of KLF4 third zinc finger motif; R458 only formed a hydrogen bond with guanine 3. See Additional
file 3: Figure S3 (I) β-galactosidase reporter activity in control and T-ALL lymphoblasts transfected with β-gal construct. The experiments were
repeated thrice and results were reported as relative β-gal activity. *P < 0.05 relative to control.
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5% CO2 atmosphere. Transfected control cells displayed
increased transcriptional activity of the reporter con-
struct containing the P21CIP promoter compared with
T-lymphoblasts (Figure 4I), suggesting that mutant
KLF4 protein in T-ALL loses its ability to bind to the
KLF4-binding site present in the P21CIP promoter, and
is thus unable to induce P21CIP. In contrast, wild-type
KLF4 protein bound to its putative site in the P21CIP
promoter and induced its expression in control T-cells.Role of SP1 in KLF4-mediated gene expression
KLF4 has been widely recognized to control cell cycle
progression through the induction of P21CIP and subse-
quent repression of CCND1 expression [20,21]. It also
represses transcription factor SP1 expression, which
regulates genes involved in apoptosis (AATF) and cell
proliferation (MYC and BCL3) [22,23]. We therefore in-
vestigated the relationship between miR-2909-modulated
KLF4 and the genes involved in cellular proliferation
and apoptosis. Both B- and T-lymphoblasts derived from
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sion levels of P21CIP mRNA and protein (Figure 5A and C),
while mRNA levels of BCL3, MYC and AATF were signi-
ficantly upregulated (Figure 5A and B). Previous reportsFigure 5 Expression levels of genes involved in cell cycle suppression
apoptosis (AATF) in pediatric acute lymphoblastic leukemias. (A-B) qR
and AATF in B- and T-cells from patients with pediatric ALL compared with
each bar represents mean ± S.D of the experiment performed in triplicate; **P
to determine protein expression levels of P21CIP (C), CCND1 (D) and SP1 (E) in
Expression was normalized to β-actin and protein band intensities were d
mean ± S.D. of the experiment performed in triplicate; **P < 0.01; *P < 0.05
activity in both B-ALL and T-ALL samples compared with the correspondi
plasmids containing SP1 response elements, incubated for 72 h at 37°C in
thrice and results were reported as relative β-gal activity. Each bar represe
relative to control.suggest it is likely that the low expression levels of P21CIP
were responsible for the overexpression of CCND1 in both
B-ALL and T-ALL (Figure 5D). However, the molecular
regulation of KLF4-driven genes such as BCL3, MYC and(KLF4, P21CIP), cell proliferation (MYC, CCND1, BCL3, SP1) and
T-PCR analysis for expression level of genes including P21CIP, BCL3, MYC
the corresponding controls. Expression was normalized to β-actin and
< 0.01; *P < 0.05 relative to control B and T cells. (C-E) Western blotting
both B- and T-lineage blasts compared with corresponding controls.
etermined using Scion Image Analysis Software. Each bar represents
relative to control B and T cells. (F) SP1 transcription factor promoter
ng controls. B- and T-lymphoblasts were transfected with reporter
humidified 5% CO2 atmosphere. The experiments were repeated
nts mean ± S.D of the experiment performed in triplicate *P < 0.05
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all the above-mentioned genes contain SP1-binding sites
(data not shown) and KLF4 has the ability to downregulate
SP1 expression, we explored the role of SP1 in this mo-
lecular regulation. SP1 protein levels were significantly
elevated in both B-ALL and T-ALL samples (Figure 5E).
To confirm that the elevated SP1 levels were transcrip-
tionally active, we transfected B- and T-lymphoblasts
with reporter plasmids containing SP1 response elements
and found that SP1 promoter activity was dramatically
increased in both B- and T-lineage blasts compared with
corresponding controls (Figure 5F). These results indicate
that the reduced expression levels of KLF4 in B-ALL and
mutant KLF4 in T-ALL were unable to repress SP1 ex-
pression, resulting in increased SP1 levels, which in turn
upregulated BCL3, MYC, and AATF expression in both
cell types.
miR-2909 regulates cell cycle and apoptosis in B- but not
T-lymphoblasts from patients with pediatric ALL
We wanted to determine if the above-mentioned genes were
upregulated as a consequence of miR-2909 overexpression
in B-ALL. B-lymphoblasts were transfected withFigure 6 Effect of miR-2909 knockdown on the expression level of va
qRT-PCR analysis of genes for KLF4, P21CIP, BCL3, MYC, AATF in B- (A) and T-
with lymphoblasts transfected with control scrambled RNA (50nM). The da
genes in B- and T-lymphoblasts were compared with control B- and T-cells
KLF4 protein levels in antagomiR-2909 transfected B- (B) and T-lymphoblas
Densitometric analysis of protein bands was carried out using Scion Image
performed in triplicate *P < 0.05 relative to control.antagomiR-2909 to knockdown miR-2909 expression,
resulting in significant upregulation of KLF4 and
P21CIP and downregulation of MYC, BCL3 and AATF
mRNAs compared with B-lymphoblasts transfected
with control scrambled RNA (Figure 6A). KLF4 pro-
tein levels were also significantly increased in these cells
(Figure 6B). In contrast, antagomiR-2909-transfection of
T-lymphoblasts had no significant effect on any of the
above genes or on KLF4 protein levels compared with T-
lymphoblasts transfected with control scrambled RNA
(Figure 6C and D). These results thus revealed that miR-
2909 plays a key role in the regulation of P21CIP, KLF4,
AATF, BCL3, MYC and CCND1, which control the cell
cycle and apoptosis in B-ALL, while miR-2909 loses the
capacity to regulate the expression of these genes in T-
ALL because they harbor a mutated miR-2909-binding
site in the 3′UTR of KLF4 and a mutated KLF4 protein.
We also evaluated the physiological relevance of the
miR-2909-regulated genes in the control of the cell cycle
and apoptosis in both B-ALL and T-ALL using flow
cytometry analysis of antagomiR-2909-transfected cells.
The percentage of cells in G1 phase of the cell cycle was
dramatically increased, whereas the percentage of cells in Srious genes in pediatric patients with B-ALL and T-ALL. (A,C).
lymphoblasts (C) transfected with antagomiR-2909 (50nM) compared
ta representation of mRNA expression levels of the above-mentioned
incubated for 48 h at 37°C in humidified 5% CO2 atmosphere. (B,D)
ts (D) compared with lymphoblasts transfected with scrambled RNA.
Analysis Software. Each bar represents mean ± S.D of the experiment
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G1–S phase (Figure 7A) in B-lymphoblasts transfected with
antagomiR-2909 compared with control scrambled RNA-
transfected B-lymphoblasts. Additionally, antagomiR-2909-Figure 7 Effect of miR-2909 knockdown on cell cycle and apoptosis in
T-lympoblasts (C) transfected with antagomiR-2909 (50nM) compared with
percentage of cells in the G1 and S phases of the cell cycle was calculated
apoptosis in B- (B) and T-lymphoblasts from patients with pediatric ALL (D
48 h. Each bar represents mean ± S.D of the experiment performed in triptransfected B-lymphoblasts showed significantly increased
apoptosis as a consequence of downregulation of the
AATF gene (Figure 7B). In contrast, suppression of miR-
2909 expression in T-lymphoblasts by antagomiR-2909both B-ALL and T-ALL. (A,C) Cell cycle analysis of B- (A) and
control scrambled RNA-transfected lymphoblasts for 48 h. The
with Cell Quest Pro Software. (B,D) Flow-cytometric detection of
) relative to control scrambled RNA-transfected lymphoblasts for
licate; *P < 0.05 with respect to control.
Figure 8 Overexpression of miR-2909 in HeLa cells confirms its oncogenic properties. (A) Endogenous levels of KLF4 protein in indicated
cell lines. (B) Representative fluorescent microscopic image indicating GFP expression in HeLa cells transfected with pMIRH-2909 expression vector
compared with control null vector containing scrambled sequence. (C-F) Protein expression levels of KLF4 (C), P21CIP (D), MYC (E) and CCND1
(F) in HeLa cells transfected with PMIRH-2909 compared with controls. Densitometric analysis of protein bands was performed using Scion Image
Analysis Software. β-actin was used as an invariant control; Each bar represents mean ± S.D. of the experiment performed in triplicate; *P < 0.05
relative to control. (G) Schematic model to summarize the critical role of miR-2909 dependent pathway in B-ALL and T-ALL. As shown, miR-2909
is functionally active and regulates KLF4 and other genes involved in cell cycle progression and apoptosis in pediatric B-ALL while its control over
the regulation of KLF4 and other genes is lost because of mutations in the KLF4 3′UTR, which includes the miR-2909 binding site and the altered
third zinc finger motif sequence of KLF4 in pediatric T-ALL.
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G1 and S phases of the cell cycle (Figure 7C) and apop-
tosis (Figure 7D) relative to T-lymphoblasts transfected
with scrambled RNA, further confirming that the mutant
KLF4 in T-ALL was non-functional.Overexpression of miR-2909 in HeLa cells induces the
expression of oncogenes
The elevated levels of miR-2909 in B-ALL reduced expres-
sion of the tumor suppressor KLF4, thus signifying its
oncogenic potential. To investigate its oncogenic nature
Malik et al. Molecular Cancer 2014, 13:175 Page 11 of 16
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(Figure 2B) and high levels of KLF4, were transfected with
the PMIRH-2909 expression vector to increase miR-2909
expression (Figure 8A and B), and protein expression levels
of KLF4, MYC, P21CIP, and CCND1 were analyzed. KLF4
and P21CIP expression levels were decreased (Figure 8C
and D) and MYC and CCND1 levels were increased
(Figure 8E and F) in HeLa cells transfected with PMIRH-
2909 compared with controls. These results confirm that
miR-2909-mediated suppression of KLF4 results in failure of
P21CIP induction and promotion of cell proliferation through
upregulated expression of CCND1 and MYC proteins.
Discussion
Mounting evidence has established KLF4 as a tran-
scriptional activator, repressor, tumor suppressor and
an oncogene, depending on its genetic context [8]. How-
ever, the exact molecular mechanisms whereby KLF4
fulfills these roles remain unknown. Moreover, the
pathway regulating KLF4 expression has not been well
studied. The present study therefore aimed to investi-
gate the miR-2909-mediated regulation of KLF4 and its
downstream functions, especially cell cycle regulation and
apoptosis, in both patients with B- and T-ALL. To the best
of our knowledge, the results provide the first evidence for
two novel mutations in the KLF4 gene in T-ALL: a muta-
tion in the 3′UTR resulted in loss of miR-2909-mediated
regulation, and mutation in the Zf1/Zf3 motif rendered
KLF4 transcriptionally inactive. In contrast, KLF4 is regu-
lated post-transcriptionally by miR-2909, and suppression
of its expression resulted in loss of KLF4 tumor suppressor
activity in pediatric B-ALL.
Previous studies involving a variety of epithelial tu-
mors have shown that the expression of the zinc-finger
transcription factor KLF4 is silenced by promoter hyper-
methylation [9]. KLF4 is also known to be inactivated by
methylation in adult T-cell leukemia [24]. Recent studies
have revealed direct correlations between altered miRNA
levels and progression of hematological malignancies,
such as the effects of downregulation of miR-15a and
miR-16-1 in chronic lymphocytic leukemia [13] and
amplification of miR-155 in B-cell lymphoma, Hodgkin’s
lymphoma [25], Burkitt’s lymphoma [26] and in human
breast cancer cell lines [27]. However, the role of miR-
NAs in the pathogeneses of pediatric B- and T-cell ALL
remains unknown. Earlier studies from our laboratory
reported that the AATF gene encodes miR-2909, the
functional importance of which remains unexplored in
terms of the pathogeneses of B- and T-cell ALLs. We
therefore investigated the expression of miR-2909 and
its regulation of its target gene KLF4. miR-2909 levels
were significantly elevated in both B- and T-ALL com-
pared with corresponding age-matched control sub-
jects. Moreover, we found a reciprocal relationshipbetween miR-2909 and KLF4 expression in B-ALL, but
not in T-ALL, which displayed significantly higher
levels of KLF4 expression despite elevated levels of
miR-2909. The observed low levels of KLF4 in B-ALL
compared with healthy subjects were in accordance
with a previous report [9].
We subsequently explored the possibility that patients
with T-ALL may harbor mutations in the KLF4 3′UTR,
which includes the miR-2909 binding site. Sequence
analysis of the 3′UTR revealed altered nucleotides in the
‘seed region’, which is important for target specificity, in
T-ALL but not in B-ALL patients. We further demon-
strated that miR-2909 targeted the KLF4 3′UTR isolated
from B-ALL patients, resulting in repression of KLF4
protein, but not that isolated from T-ALL patients with
the mutated miR-2909 binding site, leading to increased
levels of KLF4 protein. Using an miRNASelect pMIR-
GFP reporter assay, we confirmed that miR-2909 tar-
geted KLF4 in B-ALL but not in T-ALL by constructing
plasmids containing the 3′UTR and the miR-2909
target site from the B-cell (pGFP-KLF4-3′UTR-B) and
T-cell lineages (pGFP-KLF4-3′UTR-T). Transfection of
the pGFP-KLF4-3′UTR-B plasmid into HEK 293 cells re-
sulted in a 52.07% reduction in GFP expression, whereas
cells expressing pGFP-KLF4-3′UTR-T showed no notice-
able difference compared with cells transfected with pGFP
plasmid without the 3′UTR insert. These results clearly
revealed the ability of miR-2909 to repress KLF4 expres-
sion in pediatric ALL B-cell, but not T-cell lineages. Our
results thus highlight the molecular differences in miR-
2909-mediated differential regulation of KLF4 between
B- and T-ALL. Importantly, our results identifying
KLF4 as a target of miR-2909 in B-ALL are similar to
published reports of miRNA-145-mediated repression
of KLF4 in human embryonic stem cells [28] and miR-
10b regulation of KLF4 in human esophageal cancer cell
lines [29]. However, these results in pediatric T-ALL
provide the first functional demonstration of loss of
repression of any target gene as a result of a mutated
seed sequence for any miRNA in any disease.
We also explored why elevated KLF4 levels failed to
control excessive proliferation in T-ALL patients by
amplifying the full-length KLF4 sequences from B- and
T-ALL samples. Most patients with B-ALL expressed
KLF4 isoform 1, while T-ALL patients expressed isoform
2. However, the precise contributions of each isoform to
the overall functions of KLF4 are not well understood
and it will be interesting to validate these findings in a
larger cohort to improve our understanding of its impli-
cations for the pathogeneses of ALL. In addition to
identifying the isoforms present in B- and T-ALL, we
also discovered nucleotide insertions or deletions in the
Zf1 or Zf3 motif in pediatric T-ALL samples, resulting
in frameshift mutations and complete alteration of the
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troy its DNA-binding affinity.
The crystal structure of the zinc-finger domain of
KLF4 bound to target DNA was recently reported [30],
and we exploited this structural information to construct
homology models and perform docking studies of wild-
type and mutant KLF4 with the 10-bp KLF4 target DNA
sequence (5′-cgggcggggc-3′). The modeled structure of
the Zf3 motif in the mutant KLF4 revealed the replace-
ment of three key residues (C462V, C465M and H482F)
involved in coordination with zinc. Moreover, the dock-
ing results demonstrated that mutant KLF4 was unable
to interact with its 10-bp target sequence in the p21CIP
gene promoter, while wild-type KLF4 displayed cation-π
and hydrogen-bonding interactions with its target se-
quence in controls. These results clearly demonstrate
the importance of the Zf3 motif in KLF4-mediated func-
tional regulation of its target gene. These findings are
consistent with a previous study demonstrating that
KLF4-mediated macrophage differentiation was pri-
marily controlled by the two C-terminal Zf2 and Zf3
motifs, while Zf1 imparted little specificity [30]. More
importantly, we provided experimental proof to support
the docking studies, showing that mutant KLF4 in T-
lymphoblasts was unable to induce p21CIP promoter
activity, while KLF4 in control T-cells increased p21CIP
promoter reporter activity. A similar phenomenon was
reported in colorectal cancer cell lines, where KLF4 muta-
tions resulted in reduced p21CIP promoter activity [31].
KLF4 acts as cell cycle regulator and functions as a
tumor suppressor through its ability to induce p21CIP
[20] and suppress SP1 expression [22]. Based on these
findings, we studied the expression levels of genes in-
volved in this process in ALL patients. We observed
significant reductions in p21CIP and increases in SP1 in
B-ALL as a result of suppressed KLF4 expression. In
contrast, elevated levels of mutant KLF4 failed to induce
p21CIP or inhibit SP1 expression in T-ALL, leading to
low levels of p21CIP and high levels of SP1, respectively.
Moreover, the increased levels of SP1 were associated
with increased transcriptional activity of a reporter con-
struct containing an SP1 response element in both B-
and T-ALL subtypes. Earlier work from our laboratory
showed that SP1 upregulated AATF and MYC gene in
Jurkat cells [23]. Additionally, bioinformatics analysis
revealed the presence of an SP1 response element in the
promoter regions of AATF, MYC and BCL3 (data not
shown). Consistent with these results, we also confirmed
that upregulated SP1 levels resulted in increased BCL3,
AATF and MYC expression in both B- and T-ALL sub-
types. Our results therefore suggest that KLF4-mediated
regulation of these genes most likely occurs through SP1
in both B- and T-ALL. The current study also assessed
the key role of miR-2909 in the regulation of the above-mentioned genes. Results in B-lymphoblasts transfected
with antagomiR-2909 confirmed that miR-2909 regulates
these genes through KLF4. Transfection of pediatric B-
lymphoblasts with antagomiR-2909 for 48 h resulted in
significant upregulation of KLF4 expression. Further-
more, antagomiR-2909-transfected B-lymphoblasts
revealed significant repression of the AATF, MYC and
BCL3 genes. In contrast, antagomiR-2909-transfection
had no such effects in pediatric T-lymphoblasts, as a
result of failure of miR-2909 to bind to the mutated 3′
UTR of KLF4 and mutated KLF4 protein. We subse-
quently tested the functional relevance of increased KLF4
in antagomiR-2909-transfected B- and T-lymphoblasts.
B-lymphoblasts showed cell cycle arrest at G1/S phase,
most likely through increased expression of p21CIP, and
increased apoptosis, possibly resulting from AATF sup-
pression. However, no such changes were seen in
antagomiR-2909-transfected pediatric T-lymphoblasts,
despite increased levels of KLF4, which was rendered
transcriptionally inactive as a result of the altered Zf3
motif, which lacked DNA-binding activity. In addition,
antagomiR-2909-transfected B-lymphoblasts also exhibited
decreased mRNA expression of MYC and BCL3 mRNA
expression levels, which may reduce cell proliferation.
These results were similar to other reported studies show-
ing increased expression of p21CIP and decreased expres-
sion of MYC and cyclin D2 in pro/pre-B cells expressing
KLF4 [32]. Furthermore, miR-2909 overexpression and its
ability to target the tumor suppressor KLF4 suggest that it
displays oncogenic properties in B-ALL. To prove this, we
overexpressed miR-2909 in HeLa cells to silence KLF4 ex-
pression. This resulted in significantly increased CCND1
and MYC and decreased p21CIP protein levels. These re-
sults are consistent with previous findings, which showed
that KLF4-silencing in HeLa cells promoted cell growth
and tumor formation [33].
Collectively, our experimental results suggest the exist-
ence of a molecular pathway as depicted in Figure 8G,
which summarizes the differential nature of the miR-
2909-KLF4 axis in B-ALL and T-ALL. The proposed
pathway explains how high mutant KLF4 protein expres-
sion in T-ALL subjects is unable to induce p21CIP, which
plays a major role in inhibiting CCND1 expression. Mu-
tant KLF4 protein also failed to repress SP1 expression,
a gene known to be downregulated by KLF4, in parallel
with upregulation of the oncogenes MYC, BCL3 and the
anti-apoptotic AATF, potentially leading to unbridled T-
cell transformation. A similar phenomenon is proposed
in B-ALL subjects, wherein downregulation of KLF4
protein by miR-2909 overexpression results in B-cell
transformation. Significantly, our studies revealed two
breakpoints in the miR-2909-KLF4 axis caused by muta-
tion in the 3′UTR-KLF4 and the altered Zf3 motif
sequence, leading to loss of miR-2909 binding to the
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quences in target genes in T-cell ALL subjects. More-
over, structural modeling of the zinc-finger motif of
KLF4 uncovered the precise molecular basis of loss of
DNA binding in T-ALL, associated with alterations of
three key amino acid residues involved in zinc coordin-
ation. Overall, our findings suggest that KLF4 function
is compromised in T-cells derived from patients with
pediatric T-ALL because of alteration of the Zf3 motif
sequence as a result of a frameshift mutation. Further-
more, its regulation by miR-2909 is impaired because of
a mutation in the miR-2909 target sequence present in
the 3′UTR of the KLF4 mRNA. In B-ALL subjects,
KLF4 function is compromised because of miR-2909-
dependent downregulation. KLF4 is therefore unable
to act as a tumor suppressor gene in either pediatric
B-ALL or T-ALL. These results raise the possibility of
the existence of similar KLF4 mutations in other tissues.
However it was not possible to investigate the presence
of such mutations in other tissues from the study pa-
tients because of ethical considerations.
Conclusions
The present study discovered that elevated levels of the
novel miR-2909 target the tumor suppressor KLF4,
which regulates the cell cycle and apoptosis in pediatric
ALL. miR-2909-mediated downregulation resulted in
loss of KLF4 activity in B-ALL. In contrast, miR-2909
failed to regulate KLF4 expression in T-ALL because of
mutations in the KLF4 3′UTR, which includes the miR-
2909 binding site. The molecular defect responsible for
loss of KLF4 function in T-ALL despite its elevated level,
lies within the Zf3 motif, which is altered as a result of a
frameshift mutation. Homology modeling/docking stud-
ies and p21CIP promoter activity confirmed the lack of
functional activity of mutant KLF4. Comprehensive se-
quence analysis of KLF4 identified the predominance of
isoform 1 in most patients with pediatric B-ALL, and of
isoform 2 in patients with T-ALL. These results demon-
strate the existence of a novel miR-2909-KLF4 molecular
axis able to differentiate between B- and T-ALL patho-
geneses, and which may provide a new diagnostic/prog-
nostic marker to evaluate the pathogenesis of ALL in
pediatric subjects. Our results also suggest that screen-
ing for these two mutations could be developed as a
diagnostic strategy to differentiate between these two
ALL subtypes. Overall, this study provides the basis for
further research that could lead to a novel therapeutic
approach for patients with B-and T-cell ALL.
Materials and methods
Materials
The reagents were procured as follows: MiniMACS™
Starting Kit (Miltenyi Biotech, Auburn, CA); miRNeasymini kit, miScript Reverse transcription kit, miScript
SYBR Green kit, Universal primer for amplifying miR-
2909, Pfu polymerase (Fermentas, Vilnius, Lithuania);
Qiaquick PCR purification kit (Qiagen, Valencia, CA);
pBlue TOPO reporter vector, Lipofectamine 2000 and β
Gal Assay Kit (Invitrogen,Carlsbad, USA); anti-KLF4
(Abcam), anti-p21CIP, anti-SP1, anti-MYC, anti-CCND1,
anti-β actin; Annexin V-FITC apoptosis kit (Sigma-
Aldrich, St.Louis, MO, USA); pMIR-GFP Reporter Vector
(Cell Biolabs, San Diego, CA, USA); miRCURY LNA™
miR-2909 power inhibitor (EXIQON, Denmark); PMIRH-
2909 lentiviral construct (System Biosciences, CA, USA).
Patient samples
The pediatric B-ALL, T-ALL samples and age-matched
control samples were obtained from Advanced Pediatric
Centre, Post Graduate Institute of Medical Education
and Research (PGIMER), Chandigarh, India with prior
consent from their guardian through ethical approval by
the Institutional Review Board of PGIMER. Total sam-
ples of B-ALL and T-ALL were 30 and 20 respectively.
Age-matched subjects (n = 50) with no manifestations of
any haematological malignancy were treated as control.
All patients were <14 years of age and flow cytometric
immunophenotyping showed mostly cells in the blast/
progenitor region (SSC low to moderate, CD45 negative
to dim) comprising ~80% of all singlet events acquired.
Patients undergoing chemotherapy and cases with mixed
phenotype acute leukemia (MPAL) and relapsed cases
from pediatric acute lymphoblastic leukaemia (ALL) were
excluded in the present study. Diagnosis of pediatric ALL
samples into B- and T-cell lineage was evaluated by
immunophenotyping using CD19, CD22, CD79a, CD10,
CD20, and CD24 for B-ALL and CD7,CD2,CD3,CD5 for
T-ALL. Mononuclear cells were isolated using Ficoll-
Hypaque density gradient method [34]. B- and T-cells
were purified using MiniMACS™ Separator Kit.
RNA Extraction, cDNA synthesis and qRT-PCR
Total RNA including the small RNA was extracted from
patient samples using miRNeasy mini kit in accordance
with the manufacturer’s instructions. The quality and
quantity of extracted RNAs were analyzed using electro-
phoresis and optical density measurement at 260 nm;
cDNA synthesis was performed via miScript Reverse tran-
scription kit as per suppliers’s instructions. For assaying
gene expression, miScript SYBR Green Mix and the Real-
time PCR (Stratagene, San Diego, CA, USA) were used.
The qRT-PCR reaction was performed with a starting
temperature of 95°C for 10 min, followed by 35 cycles of
45 s at 94°C, 30 s at 56°C, and 45 s at 72°C. The small
non-coding nuclear RNA U6 and β-actin were used as
an invariant controls for normalizing the expression of
miR-2909 and other genes respectively. The 2-ΔΔCT
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target genes.
Immunoblotting
Total cellular protein was extracted using Laemmli’s buffer
[35] and the protein levels of KLF4, p21CIP, SP1, MYC and
CCND1 was determined through western blotting using
appropriate antibodies as described previously [36]. β-actin
antibody was used as an internal control. Scion Image
Analysis software was used for densitometry analysis and
the results were expressed as intensity ratio of target pro-
tein to β-actin protein taken as arbitrary unit.
DNA sequencing
Primer sets were designed to amplify the full coding re-
gion and 3′untranslated region of KLF4 in ALL samples
using Pfu polymerase. The resultant PCR products were
purified using Qiaquick PCR purification kit and se-
quenced to detect the presence of any genetic aberration
(s) in KLF4 in samples from pediatric patients with ALL.
The sequence data was analysed using Cluster X 2.0.12
Software (http://www.clustal.org/clustal2) [37].
Plasmid constructs and reporter assays
Full length 3′UTR of KLF4 in B-ALL was cloned into
miRNASelect™ pMIR GFP reporter vector; designated as
pGFP-KLF4-3′UTR-B which carried no substitution of
nucleotides within miR-2909 target site in KLF4 3′UTR.
Mutant 3′UTR of KLF4 present in T-ALL was named as
pGFP-KLF4-3′UTR-T with substitution of nucleotides
within core binding site in KLF4 3′UTR. The plasmid
constructs were transfected in HEK-293 cells. After
48 h, fluoresence microscopy and FACS analysis was
performed to quantitate the number of cells expressing
GFP. For p21CIP promoter analysis, promoter sequence
of p21CIP with putative KLF4 binding site was cloned
into pBlue TOPO reporter vector with subsequent
transfection of β-gal construct into control and T- lym-
phoblasts. For analysis of SP1 transcriptional activity,
B- and T-lymphoblasts with reporter plasmids contain-
ing SP1 response elements were transfected. β galactosi-
dase activity was measured 72 h after transfection. To
knockdown miR-2909 expression, leukemia cells were
transfected with miRCURY LNA™ miR-2909 power inhibi-
tor. To increase miR-2909 expression, HeLa cells were
transfected with the PMIRH-2909 expression vector. All
the transfections were performed with Lipofectamine
2000 transfection reagent according to the manufac-
turer’s instructions.
Cell cycle analysis and apoptosis assays by Flow
cytometry
Cell cycle analysis and apoptotic assays was done on
leukemia cells transfected with antagomiR-2909 (50 nM)and scrambled RNA (50 nM) for 48 h in RPMI 1640
medium supplemented with 10% FBS, 100 U/ml penicillin
and 100 μg/ml streptomycin under 5% CO2 at 37°C. For
cell cycle experiments, cells were fixed in 70% ethanol and
stained with PI. Cells percentage at different phases were
analysed with FACSCalibur cytometer and Cell Quest Pro
software (Becton Dickinson, NJ, USA). For apoptosis
assays, cells were stained with FITC Annexin V coupled
with propidium iodide and apoptosis was measured
using BD FACS Diva Software (Becton Dickinson,
FACS Canto II).
KLF4 structural model & docking with target DNA
The structural models of zinc finger motifs of wild-type
and mutant KLF4 were modeled with template PDB ID:
2WBUA. The Homology models were built using MOD-
ELLER (9.9) [38]. Model validation was performed using
Verify-3D (http://nihserver.mbi.ucla.edu/Verify_3D/) [39]
and PROCHECK [40]. The quality of the final models was
evaluated from Ramachandran plot (Additional file 3:
Figure S3B). Molecular visualization and structural align-
ment was done using CHIMERA http://bioinformatics.
org/wiki/Chimera [41] and PYMOL http://www.pymol.
org/ [42]. Target DNA sequence (5′-cgggcggggc-3′) in
p21CIP promoter was modeled into B-FORM using DNA
analysis servers [43]. Docking studies were performed
using High Ambiguity-Driven bimolecular Docking
(HADDOCK) under solvated conditions [44,45]. Cation-π
interactions were analysed with CAPTURE http://capture.
caltech.edu/ [46].
Statistical analysis
Statistical analyses were performed by SPSS Windows
version 19. Data was expressed as mean ± S.D of the experi-
ments performed in triplicate. Student’s t test or Mann-
Whitney-Wilcoxon test was performed to determine the
significance of difference between two groups. Differences
were considered significant at p < 0.01 and p < 0.05.
Additional files
Additional file 1: Figure S1. Sequence analysis of KLF4 coding region
in pediatric T-ALL samples. (A-F) Representative DNA sequence align-
ment of KLF4 coding region (corresponding to the three zinc finger
motifs in exon 5) in T-ALL samples. NCBI sequence is shown for
comparison. Sequence analyses indicate insertion (A), deletion (B-F)
of nucleotides in the first or third zinc finger motif (Zf1, Zf3) of KLF4 in
T-ALL samples. These genetic aberration(s) changed the entire reading
frame, altering the sequence of KLF4 third zinc finger motif and
potentially destroying its DNA-binding affinity (G) Protein sequence
alignment of these same 6 T-ALL samples with respect to NCBI.
Identical Zf1 and Zf2 motif in pediatric T-ALL samples is highlighted.
Additional file 2: Figure S2. Sequence analysis of KLF4 coding region
in pediatric B-ALL samples. (A,B) Representative DNA (A) and protein
sequence alignment (B) of KLF4 coding region (corresponding to the
three zinc finger motifs; Zf1, Zf2, Zf3 in exon 5) in all B-ALL samples
in the present study. NCBI sequence is shown for comparison.
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zinc-fingers regions of KLF4 in samples from pediatric patients with
B-ALL, suggesting that the conformation of KLF4 was unaffected in
these patients (sample size 10).
Additional file 3: Figure S3. Structural models and docking studies
of wild-type and mutant KLF4 (A) Predicted residues in the active site of
KLF4 were Arg449, Arg467, Lys453, Gly456, His457, Arg458, Ser470,
Arg471 and His474 as given by CASTP server. Most of the active residues
reside in the second and third zinc finger motifs; Zf2 and Zf3 as indicated by
green dots. (B) Ramachandran plot of wild-type and mutant KLF4 which
was built using PROCHECK; wild- type KLF4 has 82.7% of residues in
favoured region and the remaining 16.0% in additionally allowed
regions; mutant KLF4 has 81.4% residues in the most favoured region
and remaining 17.1% in additionally allowed regions. (C-D) Representative
table exhibited the formation of hydrogen bonds between Ser 470 and
guanine (at position 11) in wild-type (C) and between Arg458 and guanine
(at position 3) in mutant (D) KLF4 (E-F) Representative table showed non-
covalent interactions, primarily electrostatic hydrophobic and Van der waals
forces between protein residues and bases (guanine and cytidine) in wild-
type (E) and mutant KLF4 (F). DNA bases within the parentheses interact
simultaneously with its corresponding protein residue. All the active site
residues in wild-type KLF4 displayed hydrophobic and Van der waal
interactions, in contrast only few active site residues in mutant KLF4
were involved in these interactions.
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